Bausch Health Cos (NYSE:BHC) Insider Sells $258,893.81 in Stock

Bausch Health Cos Inc. (NYSE:BHC) insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the transaction, the insider directly owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. This trade represents a 9.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Stock Down 5.7%

Bausch Health Cos stock opened at $6.42 on Friday. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.44. Bausch Health Cos Inc. has a one year low of $4.33 and a one year high of $8.00. The company has a 50-day simple moving average of $5.36 and a 200-day simple moving average of $5.46. The firm has a market capitalization of $2.40 billion, a P/E ratio of -2.17 and a beta of 0.38.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.30. The firm had revenue of $2.83 billion for the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. As a group, equities analysts expect that Bausch Health Cos Inc. will post 4.35 earnings per share for the current year.

Key Stories Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Upgraded to Buy: BHC was raised to Zacks Rank #2 (Buy), reflecting improved expectations for the company’s earnings and potentially supporting further near-term gains. Bausch Upgraded to Buy
• Positive Sentiment: Higher earnings estimates: Zacks analysts raised forecasts across multiple periods, including FY2027 EPS to $3.84 from $3.59 and FY2028 EPS to $3.04 from $3.02. Estimates for several 2027 and 2028 quarters were also increased, reinforcing the view that earnings momentum could drive the stock higher. Rising Earnings Estimates
• Positive Sentiment: Bausch + Lomb growth thesis: An investment analysis highlighted 9% year-over-year revenue growth in the second quarter, margin expansion and strong operating cash flow. Growth in premium intraocular lenses and branded pharmaceuticals could improve product mix, EBITDA and cash generation while supporting deleveraging. Bausch Plus Lomb Analysis
• Neutral Sentiment: Despite the estimate increases, Zacks Research continues to rate BHC Strong Sell. The broader analyst consensus is “Reduce,” with an average price target of $8, indicating limited upside relative to current trading levels.
• Negative Sentiment: Insider Aimee Lenar sold 36,827 shares worth approximately $258,894 under a pre-arranged Rule 10b5-1 plan. Although the scheduled nature reduces its significance, the transaction cut her direct holding by 9.91%. Insider Share Sale

Analysts Set New Price Targets

BHC has been the subject of several analyst reports. Royal Bank Of Canada reduced their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Zacks Research upgraded Bausch Health Cos from a “strong sell” rating to a “hold” rating in a research report on Thursday. Finally, Weiss Ratings raised Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Six investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bausch Health Cos presently has a consensus rating of “Reduce” and a consensus price target of $8.00.

Institutional Trading of Bausch Health Cos

A number of hedge funds and other institutional investors have recently made changes to their positions in BHC. Tidal Investments LLC boosted its holdings in shares of Bausch Health Cos by 2.6% in the second quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after acquiring an additional 1,276 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in Bausch Health Cos by 14.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock worth $98,000 after purchasing an additional 1,812 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in Bausch Health Cos in the second quarter worth approximately $148,000. Pictet Asset Management Holding SA lifted its position in Bausch Health Cos by 4.1% in the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock worth $292,000 after purchasing an additional 2,114 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Bausch Health Cos by 2.5% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after purchasing an additional 2,552 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.